Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases.
Marta Araujo-CastroBetina BiagettiEdelmiro Menéndez TorreIría Novoa-TestaFernando CordidoEider Pascual CorralesVíctor Rodríguez BerrocalFernando Guerrero-PérezAlmudena VicenteJuan Carlos PercovichRogelio García CentenoLaura GonzálezMaría Dolores Ollero GarcíaAna Irigaray EcharriMaría Dolores Moure RodríguezCristina Novo-RodríguezMaría CalatayudRocío VillarIgnacio BernabéuCristina Alvarez-EscolaPamela Benítez ValderramaCarmen Tenorio-JimenézPablo Abellán GalianaEva Venegas MorenoInmaculada González MoleroPedro IglesiasConcepción BlancoFernando Vidal-Ostos De LaraPaz de MiguelElena López MezquitaFelicia HanzuIban AldecoaCristina LamasSilvia AznarAnna AulinasAnna CalabresePaola GraciaJosé María Recio-CórdovaMariola AvilesDiego Asensio-WandoselMiguel SampedroIgnacio Ruz-CaracuelRosa CamaraMiguel PajaCarmen Fajardo-MontañanaMónica MarazuelaManel Puig-DomingoPublished in: The Journal of clinical endocrinology and metabolism (2024)
GH&PRL-PAs are responsible for 20% of acromegaly cases. These tumors are more invasive, larger and cause hypopituitarism more frequently than GH-PAs and are diagnosed at an earlier age. The biochemical cure rate is similar between both groups, but patients with GH&PRL-PAs tend to develop permanent postsurgical AVP-D more frequently.
Keyphrases